Research use only peptides: what the label means legally and why it matters

“Research use only” (RUO) on a peptide is the seller’s statement that the product is meant for laboratory or animal experiments, not for people. It is not an FDA approval, a prescription category or a quality grade. FDA judges a product by its intended use, not by its label. Sellers whose websites showed human use have received warning letters saying their peptides were “intended to be drugs for human use” despite the label. The strongest quality data come from product testing: three online semaglutide vials measured 7.7–14.37% purity against a claimed 99% (Ashraf 2024).

Item	Status
What the label is	A seller’s statement. FDA defines the wording “For Research Use Only” for in vitro diagnostic products (21 CFR 809.10), not for drugs
US FDA status	Not an approval. FDA treats RUO peptides marketed for human use as unapproved new drugs and has issued warning letters to online sellers, including one dated 2026-08-24 and posted 2026-09-01 (FDA)
Compounding (503A/503B)	A separate, prescription-based pathway. BPC-157 and 15 other substances withdrawn from Category 2 (FDA, 2026-04-22); PCAC votes of 2026-07-23/24 are advisory, no FDA rule yet
WADA 2026	The label gives no exemption; S0 bans any substance without government approval for human therapeutic use (WADA)
Strongest evidence	Product testing: 3 of 3 vials far below claimed purity, endotoxin in all (Ashraf 2024); a usability study, n=20
Human trials	None: RUO products are not trial drugs. Human research on an unapproved drug runs under an IND (FDA)
Next regulatory step	FDA rulemaking on the PCAC-reviewed peptides: no date announced
Last checked	2026-09-30

What does “research use only” mean on a peptide?

The phrase comes from diagnostics law. FDA’s labeling rule for in vitro diagnostic products requires the statement “For Research Use Only. Not for use in diagnostic procedures.” on products still in the laboratory research phase (21 CFR 809.10(c)(2)(i)). FDA issued a guidance in November 2013 on when diagnostic products are properly labeled RUO. Neither the rule nor the guidance creates an RUO category for drugs.

In the peptide market the phrase is used differently. Synthetic peptides are everyday laboratory tools, and labs buy them for cell and animal experiments. Many consumer-facing websites use the same wording, often alongside “not for human consumption”, on peptides that are sold to individuals. A 2025 commentary in Annals of Pharmacotherapy described sellers marketing semaglutide and tirzepatide vials “for ‘research purposes only’ and/or ‘not for human consumption’” and noted that “avoiding prescribers allows consumer access to products where the risk may outweigh the benefits” (Belcourt 2025).

Background on how peptides are classed and regulated is in what peptides are and how they are classed.

Is “research use only” a legal category for peptides?

No. Under US law a product is a drug when it is intended to diagnose, treat or prevent disease or to affect the body’s structure or function, and FDA applies that definition (FD&C Act section 201(g)(1)) to peptides sold with RUO labels (FDA warning letter, 2026-08-24). A new drug needs FDA approval before it is sold across state lines (section 505(a)). FDA states that “current Federal law requires that a drug be the subject of an approved marketing application before it is transported or distributed across state lines”, and that the Investigational New Drug (IND) application is how a sponsor obtains an exemption for clinical trials (FDA).

The deciding question is intent. FDA’s regulation defines “intended uses” as the objective intent of the people responsible for the product, shown by “labeling claims, advertising matter, or oral or written statements”, by the design of the article and by the circumstances of its sale (21 CFR 201.128). A label saying one thing does not settle the matter when the website says another.

RUO is	RUO is not
A statement by the seller	An FDA review or approval
Defined in FDA rules for diagnostics only	A drug category with its own rules
Outweighed by evidence of human use	A shield against drug law
No guarantee of content or sterility	A quality or purity grade

How FDA decides whether an RUO peptide is really a drug

FDA’s recent letters show the kinds of evidence it relies on. In a December 2024 letter, FDA wrote that “despite statements on your product labeling marketing your products as ‘RESEARCH USE ONLY’ and ‘INTENDED AS A RESEARCH CHEMICAL ONLY,’ evidence obtained from your websites establish that your products are intended to be drugs for human use”; the products were semaglutide, retatrutide, cagrilintide, tirzepatide and mazdutide (FDA warning letter, 2024-12-10). In an August 2026 letter covering retatrutide, semaglutide, SS-31, PT-141 and tesamorelin, FDA cited product descriptions about metabolism, appetite, glucose control and sexual function, and a solvent sold alongside the peptides (FDA warning letter, 2026-08-24). FDA also says such products “have been sold directly to consumers for human use with dosing instructions” (FDA).

Evidence FDA has cited	Where
Health or benefit claims on product pages	Letters of 2024-12-10 and 2026-08-24
Social media posts about weight loss	Letter of 2024-12-10
A solvent sold with the peptides	Letter of 2026-08-24
Instructions for human use	FDA GLP-1 page, 2026-09-01

Enforcement timeline

Date	Event
2024-12-17	FDA posts four warning letters over unapproved GLP-1s sold online, including retatrutide (FDA)
2026-04-22	FDA page lists BPC-157 and 15 other substances as withdrawn from Category 2; GHRP-2, GHRP-6, ipamorelin, kisspeptin-10 and ibutamoren stay (FDA)
2026-05-29	UK MHRA reports its largest seizure of unlicensed weight-loss medicines, about 12,000 doses including peptide products (MHRA)
2026-07-23/24	FDA advisory committee reviews seven peptides for 503A compounding; votes are advisory (FDA)
2026	Owner of an online peptide business sentenced to 70 months (US Attorney)
2026-08-24	FDA warning letter to an online peptide seller, dated 2026-08-24 and posted 2026-09-01 (FDA)

The compounding votes and the Category 2 changes concern licensed pharmacies, not RUO sellers; 503A vs 503B compounding explains the difference.

Why the label matters: quality, sterility and safety

Because no regulator reviews RUO products for human use, what is in the vial rests on the seller. The published tests are few, but they point the same way.

• Purity and content (product testing, 3 vials): researchers found 59 illegal online sellers of semaglutide, ordered from 6, and received 3 vials. Purity measured 7.7–14.37% against a claimed 99%, semaglutide content exceeded the label by 28.56–38.69%, and endotoxin (bacterial toxin) was found in all samples; no viable microorganisms grew. None of the sellers asked for a prescription, and two carried “not for human or animal use” disclaimers (Ashraf 2024).
• Handling errors (Human usability study, n=20): untrained adults given grey-market semaglutide and internet information completed 15 of 34 steps correctly (44%), with errors that could cause wrong amounts, needle-stick injuries or infection (Sedensky 2026).
• Adverse event (Human case report, n=1): a man with type 1 diabetes developed vomiting, diarrhea, high ketones and acute kidney injury after using an online product sold as retatrutide and labeled “not for human or veterinary consumption”; a Shigella infection complicated attribution, and he recovered after five days (Branine 2026).

These findings describe unregulated products, not the peptides themselves. Retatrutide, named in both FDA letters cited above, has been tested in registered phase 3 trials such as NCT05929066 (2,335 participants, completed), run under FDA’s investigational drug rules (FDA).

Research-grade, compounded and approved: the three routes compared

Route	What oversight applies
FDA-approved drug	Approved marketing application before sale across state lines (FDA)
Clinical trial	IND exemption from the approval requirement (FDA)
Compounded drug	Licensed pharmacy, prescription, FDA bulk-substance policy (FDA)
RUO product	None for human use; FDA acts against sellers when intent is shown

Compounding has its own limits: FDA keeps GHRP-2, GHRP-6, ipamorelin, kisspeptin-10 and the non-peptide ibutamoren in Category 2, citing concerns about “immunogenicity due to the potential for aggregation and peptide-related impurities” (FDA Category 2 page). Withdrawal from Category 2, as happened to BPC-157, is not the same as approval.

What “research use only” means for athletes

An RUO label has no standing in anti-doping rules. WADA’s S0 class covers any pharmacological substance “with no current approval by any governmental regulatory health authority for human therapeutic use”, including drugs in pre-clinical or clinical development (WADA Prohibited List 2026). USADA states that BPC-157 is prohibited under S0 (USADA). Mislabeled or contaminated products add a further risk, since an athlete is responsible for what the product actually contains. The peptide-by-peptide list is in WADA banned peptides.

Outside the United States

In the UK, the MHRA reported on 2026-05-29 that an operation recovered about 12,000 doses of unlicensed weight-loss medicines, including retatrutide, tirzepatide and peptide products, and directs the public to its #FakeMeds guidance (MHRA). The release does not mention RUO labels. This guide does not cover EU or Australian rules on RUO labels because no primary source was found that addresses them directly.